You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 R/R NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Trial in Pittsburgh (Fecal Microbiota Transplant (FMT), Pembrolizumab)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Dec 20, 2022

NSCLC, Stage IIIA, EGF-R Negative NSCLC, ALK Negative NSCLC Trial in Shanghai (PD-1 and chemo)

Recruiting
  • NSCLC, Stage IIIA
  • +2 more
  • PD-1 and chemotherapy
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Dec 14, 2021

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

NSCLC, Tumors Trial in Canada, Poland, Romania (Debio 1143, Avelumab)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Neoplasms
  • Edmonton, Alberta, Canada
  • +8 more
May 30, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022

NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy Trial in Chengdu (Low Dose Radiotherapy, stereotactic body

Not yet recruiting
  • NSCLC
  • +3 more
  • Low Dose Radiotherapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 11, 2022

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Advanced NSCLC Trial (Trilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Non-hodgkin Lymphoma,B Cell Trial (CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection)

Not yet recruiting
  • Non-hodgkin Lymphoma,B Cell
  • CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
  • (no location specified)
Feb 14, 2023

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low

Recruiting
  • NSCLC
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 28, 2022

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Dalpiciclib+cetuximab)

Recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    the Ninth People's Hospital Affiliated to Shanghai Jiao Tong Uni
Feb 9, 2023

NSCLC Trial in Nanjing (NK510, Tislelizumab,atezolizumab or sugemalimab)

Recruiting
  • NSCLC
  • NK510
  • Tislelizumab，atezolizumab or sugemalimab
  • Nanjing, Jiangsu, China
    General Hospital of Eastern Theater Command
Oct 23, 2023

DLBCL Trial (Sintilimab, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Mar 6, 2022

NSCLC Trial in Amsterdam (Ipilimumab, Cemiplimab, SBRT)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoek - Netherlands Cancer Institute
Jan 10, 2023